Quantification analysis of the expression of tumor-associated proteins in serum samples from patients with ovarian cancer and those with other tumor location. Possibilities of their use in the diagnosis and estimation of the extent of a tumorous process
https://doi.org/10.17650/1994-4098-2012-0-3-4-93-98
Abstract
The specific features of the expression of tumor-associated proteins (TAP) were immunologically studied in the sera of patients with ovarian cancer (OC) and other tumor location by means of immune sera (As) or monoclonal antibodies (MAb) to find out whether they could be used to diagnose and estimate the extent of a tumorous process.
MAb 1 (to HEp-2 cell membrane proteins, larynx cancer), Ac4 (to a pool of two ovarian cystadenocarcinomas), and MAb 3 (to affinity-pu- rified proteins of the apparently intact human gastric mucosa) were used to examine the sera of patients with OC and other tumor location and positive responsiveness was detected in 82, ~100, and 77 % of cases, respectively. The differences in the expression of TAP in the patients versus healthy donors were shown to be statistically significant (p = 0.0001; p = 0.015; p = 0.01, respectively).
The sensitivity of quantifying ELISA in detecting TAP was 78 and 85 % in patients with Stages I–II and III–IV OC, respectively; ~100 and 89 % in patients with breast cancer and in those with gastrointestinal tract cancer, respectively; and 60 and 14 % in patients with lymphopro- liferative diseases and healthy donors, respectively. Comparison of TAP detection rates in the authors’ test systems with multiplex testing with a biochip array of 12 tumor markers has shown that these test systems are at the world standard level.
About the Authors
T. S. Bobrova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Yu. V. Chuyev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. I. Zhordania
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Жорданиа К.И. Злокачественные эпителиальные опухоли яичника. Совр Онкол 2000;2(2):51−5.
2. Кидралиев Р.Р., Адамян Л.В., Жорданиа К.И. и др. Лизофосфатидиловая кислота как биомаркер рака яичника. ОЖРС 2007;1−2:80−4.
3. Сафронникова Н.Р. Профилактика и ранняя диагностика гинекологического рака. Материалы съезда онкологов и радиологов СНГ. Ч. I. Минск: ОДО Тонпик, 2004. С. 249−53.
4. Atack D.B., Nisker J.A., Allen H.H. et al. CA-125 surveillance and second-look laparotomy in ovarian carcinoma Am J Obstet Gynecol 1986;154:287−9.
5. Bast R.C., Boyer C.M., Olt G.J. Ovarian cancer. Biological and therapeutic challenges London, 1991. Pp. 265−75.
6. Borgono C.A., Grass L., Soosaipillai A. et al. Human kallikrein 14. A new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63(24):9032−41.
7. Luo L., Katsaros D., Scorilas A. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63(4):807−11.
8. Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA15-3, CA72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distribu- tions. J Clin Oncol 2004;22(20):4059−66.
9. Wong N.K., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003;278(31): 28619−34.
10. Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian carcer. Cancer Res 2004;64(16):5882−90.
11. Боброва Т.С., Чуев Ю.В. Исследование опухоле-ассоциированных белков в тканях и сыворотках крови больных карциномами молочной железы. Мед иммунол 2006; 8(5−6):645−52.
12. Боброва Т.С., Чуев Ю.В., Жорданиа К.И. Экспрессия опухоле-ассоциированных белков в тканях и сыворотках крови у больных раком яичника. ОЖРС 2008;1:65−72.
13. Закс Л. Статистическое оценивание. М.: Статистика, 1976; с. 129−53.
14. Sun Z., Fu X., Zhang L. A protein chip system for parallel analysis of multitumor markers and its application in cancer detection. Anticancer Res 2004;24:1159−66.
Review
For citations:
Bobrova T.S., Chuyev Yu.V., Zhordania K.I. Quantification analysis of the expression of tumor-associated proteins in serum samples from patients with ovarian cancer and those with other tumor location. Possibilities of their use in the diagnosis and estimation of the extent of a tumorous process. Tumors of female reproductive system. 2012;(3-4):93-98. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-3-4-93-98
Views:
501
Email this article 